Goxalapladib

CAS No. 412950-27-7

Goxalapladib( —— )

Catalog No. M35993 CAS No. 412950-27-7

Goxalapladib(GSK 677116) is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 276 In Stock
10MG 394 In Stock
25MG 616 In Stock
50MG 830 In Stock
100MG 1097 In Stock
200MG 1507 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Goxalapladib
  • Note
    Research use only, not for human use.
  • Brief Description
    Goxalapladib(GSK 677116) is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.
  • Description
    Goxalapladib(GSK 677116) is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    412950-27-7
  • Formula Weight
    718.75
  • Molecular Formula
    C40H39F5N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(N(CC1=CC=C(C=C1)C2=CC=C(C(F)(F)F)C=C2)C3CCN(CCOC)CC3)=O)N4C=5C(C(=O)C=C4CCC6=C(F)C(F)=CC=C6)=CC=CN5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Scutebarbatine A

    Scutebarbatine A shows significant antitumor effects on A549 cells in vivo and in vitro via mitochondria-mediated apoptosis by up-regulating expressions of caspase-3 and 9, and down-regulating Bcl-2.

  • β III probe

    β III probe

  • Astressin

    Astressin is an amino-terminal truncated analog of CRF that retains high affinity binding to the extracellular domain of the receptor and is believed to act as a neutral competitive antagonist of receptor activation.